#USA #Phoenix #Clinical Trial #BioLab Holdings #Human Placental Membrane

BioLab Holdings, Inc. Launches Comprehensive Clinical Trial on Wound Care Products

On July 31, 2025, BioLab Holdings, Inc., based in Phoenix, proudly announced the commencement of its largest clinical trial to date, exploring human placental membrane (HPM) products as innovative solutions in wound care. This multicenter, prospective, randomized controlled study is set to evaluate the effectiveness of four unique HPM products in treating nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), compared to standard care alone.

The trial, formally labeled "A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP)," will see the enrollment of approximately 650 participants across up to 30 clinical sites nationwide. The initiative represents a significant advancement in the realm of regenerative medicine and chronic wound treatment.

Dr. Marshall Medley, BioLab’s Chief Medical Officer, emphasized the importance of this study, stating, "This study is a major milestone in our commitment to advancing wound care through rigorous clinical research. By evaluating our full range of amnion-based products in real-world scenarios, we hope to equip clinicians with substantial data to inform their treatment decisions for patients struggling with chronic wounds."

Participants in the trial will be randomly assigned to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in conjunction with standard care, or standard care alone. The treatment regime will continue for up to 12 weeks, with weekly applications or until total wound closure is achieved, confirmed by a follow-up evaluation two weeks post-treatment. Optional weekly visits will permit dressing changes in both study groups, facilitating continuous monitoring and care.

The design of this trial aims to yield a wealth of clinical outcomes that not only substantiate the efficiency of placental-derived allografts in managing chronic wounds but also support ongoing research in regenerative medicine. With an increasing patient population for chronic wound care, findings from this trial are anticipated to pave the way for enhanced treatment protocols and innovations within the healthcare community.

BioLab Holdings, Inc. is renowned for its dedication to wound healing and regenerative solutions. Its product offerings include several advanced amniotic membrane derivatives, specifically engineered to promote healing while preserving the natural properties of the tissue. BioLab is resolute in its mission to deliver superior quality products while fostering a commitment to innovation, education, and exceptional customer service.

For additional information regarding BioLab Holdings and its range of regenerative wound care solutions, please visit biolabholdings.net.

In a field burgeoning with potential, BioLab Holdings, Inc. is poised to make a noteworthy impact in the landscape of chronic wound management, striving for excellence and evidence-based practices that promise to enhance patient outcomes significantly.

• ---

For media inquiries:
Kwyn Lowe
Phone: 406.314.5120
Email: [email protected]
Source: BioLab Holdings, Inc.